Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Lexicon
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals Incorporated
MAJ Il y a 4 ans
A Randomized, Double-Blind, Placebo-Controlled Study to Determine Safety and Tolerability of LX6171 Oral Suspension Dosed for 28 Days in Subjects Exhibiting Age Associated Memory Impairment (AAMI) with a Lead-in, Open-Label, Single-Dose Relative Bioavailability Study of LX6171 Oral Suspension in Healthy Elderly Subjects
In stage A, the primary objective is: - To compare the relative bioavailability of a single dose of 300 mg LX6171 using a 40mg/mL and an 80mg/mL formulated suspension; - To evaluate plasma concentrati...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
Efficacy and safety of adding LX4211 (an investigational oral compound) for patients with Type 1 Diabetes Mellitus (T1D) who have inadequate control of their blood glucose (sugar) levels on insulin alone
The primary objective of this study is to demonstrate superiority of either LX4211 400 mg or 200 mg versus placebo on glycosylated hemoglobin A1C (A1C) reduction at Week 24 when used as an adjunct in ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Determine the Safety and Efficacy of Daily Orally Administered LX3305 in Subjects with Active Rheumatoid Arthritis (RA) on Stable Methotrexate (MTX) Therapy
The primary objectives of this study are: • To evaluate the safety and tolerability of three dose levels of LX3305 over 12 weeks in subjects with active RA who are also receiving stable doses of MTX; ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
A study to examine the advantage of Sotagliflozin in addition to Insulin therapy in patients with Type 1 Diabetes Studie zkoumající výhody sotagliflozinu jako doplňku inzulinové léčby pacientů s diabetem I. typu
To demonstrate the superiority of sotagliflozin 400 mg versus placebo in the proportion of patients with glycosylated A1C <7.0% at Week 24 and no episode of severe hypoglycemia and no episode of diabe...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Multicenter, Long-term Extension Study to Further Evaluate the Safety and Tolerability of Telotristat Etiprate (LX1606)
The primary objective of this study is to evaluate the long-term safety and tolerability of orally administered telotristat etiprate
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 2, Open-Label, Multi-Center, Serial Ascending-Dose, Dose Finding Study to Evaluate the Safety and Tolerability of LX1606 in Subjects with Symptomatic Carcinoid Syndrome
The primary objective of this study is to evaluate the safety and tolerability of orally administered LX1606 in subjects with symptomatic carcinoid syndrome.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Phase 3, Randomized, Placebo-controlled, Multicenter, Double-blind Study to Evaluate the Safety and Efficacy of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome Estudio en fase 3, aleatorizado, multicéntrico, doble ciego y controlado con placebo para evaluar la seguridad y la eficacia de etiprato de telotristat (LX1606) en pacientes con síndrome carcinoide
To evaluate the effect of telotristat etiprate versus placebo over the double-blind portion of the study on the incidence of treatment-emergent adverse events (TEAEs) Evaluar el efecto del etipr...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme
Entre 18 ans
et 99 ans
Lexicon
MAJ Il y a 4 ans
Étude TELEPATH : étude d'extension, évaluant à long terme la sécurité d’emploi et la tolérance du telotristat etiprate (LX1606), chez des patients ayant un syndrome carcinoïde. [essai clos aux inclusions]
L’objectif de cette étude est de permettre la poursuite du traitement par telotristat etiprate (LX1606), au-delà des 48 semaines de traitement prévus dans les deux protocoles LX1606 301 CS et LX1606 3...
Pays
France
Organes
Cancers rares
Spécialités
Thérapies Ciblées
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Research Study of the Efficacy and Safety of Telotristat Etiprate for Carcinoid Syndrome Patients, Who Do Not Respond to Somatostatin Analogue Therapy Studio Clinico per valutare l'efficacia e la sicureza di telotristat etiprato per i pazienti con sindrome da carcinoide (SC) che non rispondono alla terapia con analoghi della somatostatina
The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the change from baseline in the number of daily bo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Lexicon Pharmaceuticals, Inc
MAJ Il y a 4 ans
A Pilot Study to Evaluate Safety and Efficacy of LX1606 in Subjects With Acute, Mild to Moderate Ulcerative Colitis
The primary objective of this study is to evaluate the safety and tolerability of orally administered LX1606 after 8 weeks in a cohort of subjects with acute, mild to moderate ulcerative colitis.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations